keyword
https://read.qxmd.com/read/34019450/-a-rare-cause-of-hypercalcemia
#1
JOURNAL ARTICLE
Luca Emmenegger, Alexander Vogetseder, Michael Bodmer
A Rare Cause of Hypercalcemia Abstract. Sarcoidosis is a rare cause of hypercalcemia, which is in most cases caused by primary hyperparathyroidism or a malignant tumor. Other rare causes include vitamin D intoxication, other granulomatous diseases (such as tuberculosis, or fungal infection) or mutiple myeloma. Because of the broad differential diagnosis, a systematic diagnostic approach is crucial to establish the correct diagnosis. Therapeutic measures include volume replacement and subsequent administration of bisphosphonates...
2021: Praxis
https://read.qxmd.com/read/33554406/avelumab-a-pd-l1-inhibitor-in-combination-with-hypofractionated-radiotherapy-and-the-abscopal-effect-in-relapsed-refractory-multiple-myeloma
#2
JOURNAL ARTICLE
Dickran Kazandjian, Alexander Dew, Elizabeth Hill, Elizabeth Gil Ramirez, Candis Morrison, Esther Mena, Liza Lindenberg, Constance Yuan, Irina Maric, Hao-Wei Wang, Katherine Calvo, Alina Dulau-Florea, Joseph Roswarski, Michael Emanuel, Raul Braylan, Boris Turkbey, Peter Choyke, Kevin Camphausen, Maryalice Stetler-Stevenson, Seth M Steinberg, William D Figg, Jennifer Jones
LESSONS LEARNED: Despite the initial optimism for using immune checkpoint inhibition in the treatment of multiple myeloma, subsequent clinical studies have been disappointing. Preclinical studies have suggested that priming the immune system with various modalities in addition to checkpoint inhibition may overcome the relative T cell exhaustion or senescence; however, in this small dataset, radiotherapy with checkpoint inhibition did not appear to activate the anti-tumor immune response...
February 8, 2021: Oncologist
https://read.qxmd.com/read/30719772/pomalidomide-dexamethasone-for-treatment-of-soft-tissue-plasmacytomas-in-patients-with-relapsed-refractory-multiple-myeloma
#3
JOURNAL ARTICLE
Raquel Jiménez-Segura, Miquel Granell, Mercè Gironella, Eugenia Abella, Antoni García-Guiñón, Albert Oriol, Elena Cabezudo, Victoria Clapés, Joan Alfons Soler, Lourdes Escoda, Jordi López-Pardo, Carlos Fernández de Larrea, Maria Teresa Cibeira, Natalia Tovar, Ignacio Isola, Joan Bladé, Laura Rosiñol
OBJECTIVE: The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedullary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide-dexamethasone combination in this patient profile...
May 2019: European Journal of Haematology
https://read.qxmd.com/read/30417559/brdu-incorporation-in-multiparameter-flow-cytometry-a-new-cell-cycle-assessment-approach-in-multiple-myeloma
#4
JOURNAL ARTICLE
Guilhem Requirand, Nicolas Robert, Stéphanie Boireau, Laure Vincent, Anja Seckinger, Salaheddine Bouhya, Patrice Ceballos, Guillaume Cartron, Dirk Hose, Bernard Klein, Jérôme Moreaux
BACKGROUND: Mutiple myeloma (MM) is a neoplasia characterized by the accumulation of malignant plasma cells (PC) in the bone marrow. Although proliferation markers have been studied in MM, none of the current staging systems include them. Moreover, approaches used to analyze proliferation do not separate MM cells (MMCs) from normal PC. METHODS: In this study, we combined multiparameter flow cytometry and BrdU incorporation or Ki67 staining to analyze MM cell proliferation in 44 monoclonal gammopathy of undetermined significance (MGUS), 153 newly diagnosed MM patients and 69 MM patients at relapse...
May 2019: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/29515796/prognostic-significance-of-the-red-blood-cell-distribution-width-that-maintain-at-high-level-following-completion-of-first-line-therapy-in-mutiple-myeloma-patients
#5
JOURNAL ARTICLE
Yongyong Ma, Zhouxiang Jin, Shujuan Zhou, Haige Ye, Songfu Jiang, Kang Yu
To investigate the prognostic value of the red blood cell distribution width(RDW) recovery from low levels at diagnosis after completion of first line therapy in mutiple myeloma (MM)patients,we enrolled 78 consecutive patients with MM and followed up from 2005 to 2016 in our hospital. The RDW was measured following completion of first-line therapy.The log-rank test, univariate analysis, and Cox regression analysis were used to evaluate the relationship between RDW and survival. We found that patients with an RDW ≥ 15...
February 9, 2018: Oncotarget
https://read.qxmd.com/read/29200389/-circulating-exosomal-microrna-as-biomarkers-in-mutiple-myeloma
#6
Salomon Manier, Xavier Leleu, Hervé Avet-Loiseau
No abstract text is available yet for this article.
November 2017: Médecine Sciences: M/S
https://read.qxmd.com/read/27728325/mutiple-myeloma
#7
JOURNAL ARTICLE
Shriram Agrawal
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://read.qxmd.com/read/27268630/ki-67-immunostaining-and-its-correlation-with-microvessel-density-in-patients-with-mutiple-myeloma
#8
JOURNAL ARTICLE
Bhankar Himani, Sikka Meera, Sharma Abhimanyu, Rusia Usha
PURPOSE: To compare Ki-67 index and microvessel density MVD) in multiple myeloma and non-myeloma patients and their correlation with each other and other prognostic markers. MATERIALS AND METHODS: Forty patients were enrolled in this study between 2011-2013, 30 with multiple myelomas and 10 with non-malignant disease as controls. Proliferative activity was analyzed by Ki-67 and microvessel density (MVC) was assessed by CD34 and compared between two groups. In myeloma patients, correlation between Ki-67, MVD and other prognostic factors was assessed by Pearson correlation coefficient...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/25641146/-the-characteristics-of-62-cases-of-cd20-positive-multiple-myeloma
#9
JOURNAL ARTICLE
Zengjun Li, Yan Xu, Gang An, Huijun Wang, Shuhui Deng, Yaozhong Zhao, Lugui Qiu
OBJECTIVE: To explore the clinical and laboratory characteristics of mutiple myeloma patients with CD20 expression. METHODS: Review the data of mutiple myeloma patients and analyze the clinical and laboratory characteristics of CD20 positive patients, compared with CD20 negative patients. RESULTS: (1)Totally 465 cases of newly-diagnosed MM were collected with CD20 expression status detected by multi-color flow cytometry. Sixty two patients (13...
January 2015: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/24424232/diffuse-plasma-cell-infiltration-of-liver-detected-initially-at-diagnosis-of-multiple-myeloma
#10
JOURNAL ARTICLE
T Guney, S M Bakanay Ozturk, T Hacibekiroglu, S Akinci, A Basturk, I Dilek
Liver involvement in mutiple myeloma (MM) is not commonly encountered. In this report, we describe a patient who was diagnosed with IgG kappa type MM. A liver biopsy revealed monoclonal plasma cell infiltration. Hepatomegaly was the sole finding in physical examination and the liver function tests were not disturbed.
2013: La Clinica Terapeutica
https://read.qxmd.com/read/23912663/long-term-outcome-of-patients-with-multiple-corrected-myeloma-related-advanced-renal-failure-following-auto-sct
#11
JOURNAL ARTICLE
S V Glavey, M A Gertz, A Dispenzieri, S Kumar, F Buadi, M Lacy, S R Hayman, P Kapoor, D Dingli, A McCurdy, W J Hogan, D A Gastineau, N Leung
Renal failure commonly complicates multiple myeloma (MM) and is associated with reduced survival. It is not clear whether auto-SCT results in improved renal function or attainment of independence from dialysis in patients with advanced renal impairment due to MM. We conducted a retrospective cohort study of all patients who underwent auto-SCT for MM complicated by advanced renal failure at our institution over a 10-year period (2000-2010). We aimed to assess the association between auto-SCT and renal outcome in patients with serum creatinine (SCr) over 3 mg/dL, attributable to MM, including those who were dialysis dependent...
November 2013: Bone Marrow Transplantation
https://read.qxmd.com/read/23894411/mir-19a-an-effective-regulator-of-socs3-and-enhancer-of-jak-stat-signalling
#12
JOURNAL ARTICLE
Aideen S Collins, Claire E McCoy, Andrew T Lloyd, Cliona O'Farrelly, Nigel J Stevenson
Suppressors of cytokine signalling (SOCS) proteins are classic inhibitors of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Many cytokines and pathogenic mediators induce expression of SOCS, which act in a negative feedback loop to inhibit further signal transduction. SOCS mRNA expression is regulated by DNA binding of STAT proteins, however, their post-transcriptional regulation is poorly understood. microRNAs (miRNAs) are small non-coding RNAs that bind to complementary sequences on target mRNAs, often silencing gene expression...
2013: PloS One
https://read.qxmd.com/read/22900137/multiple-occipital-defects-caused-by-arachnoid-granulations-emphasis-on-t2-mapping
#13
JOURNAL ARTICLE
Chao-Xuan Lu, Yong Du, Xiao-Xue Xu, Yang Li, Han-Feng Yang, Shao-Qiang Deng, Dong-Mei Xiao, Bing Li, Yun-Hong Tian
A 56-year-old man presented with a 6-mo history of headache. Although neurological and laboratory examinations were normal, computed tomography (CT) scan was performed which revealed multiple occipital osteolytic lesions, which were suspected to be multiple myeloma. Subsequently nuclear magnetic resonance imaging (MRI) showed that these lesions presented with a cerebrospinal fluid (CSF)-like signal intensity, no diffusional restriction and intrinsic mass-like enhancement on conventional sequences were seen...
July 28, 2012: World Journal of Radiology
https://read.qxmd.com/read/12425200/-therapeutic-results-and-changes-in-prognosis-in-patients-with-multiple-myeloma-in-central-and-northern-moravia-over-the-past-40-years
#14
MULTICENTER STUDY
V Scudla, J Bacovský, K Indrák, V Kod'ousková, M Vytrasová, E Faber, T Papajík, V Vavrdová, Z Adam, R Hájek, V Farbiaková, K Srovnalík, L Novosadová, M Vránová, M Micaníková, E Sumná, B Kuca, J Slezar, V Heincová, J Gumulec, J Zivná, P Schlemmer, E Lautnerová, Z Lasota, M Kubecková, I Krajsová, M Růzicka, K Cíhal, A Martínek, B Cernosek, J Doubravský, J Papajík, P Prodĕlal
OBJECTIVE: The objective of the investigation is evaluation of therapeutic results and the development of the prognosis of patients with multiple myeloma (MM) as a result of consecutive changes of therapeutic procedures in patients of central and northern Moravia in the course of the last 40 years. METHODS AND RESULTS: The analyzed group of 562 patients with MM was concentrated at the Ist and IIIrd Medical Clinic of the Faculty Hospital Olomouc in 1959 - 2000, median age 63 (28-91) male/female ratio 1...
August 2002: Vnitr̆ní Lékar̆ství
https://read.qxmd.com/read/11033458/analysis-of-the-expressed-immunoglobulin-variable-region-heavy-chain-gene-products-in-paraproteins-from-iranian-patients-with-multiple-myeloma
#15
JOURNAL ARTICLE
S Gharagozloo, R A Sharifian, R A Mageed, F Shokri
The frequency of expression of immunoglobulin (Ig) variable region heavy (VH ) chain gene products was studied in 43 Iranian patients with mutiple myeloma (MM). The expressed VH gene families and associated cross-reactive idiotypes (CRI) were analysed by immunoblotting and ELISA, using peptide-induced polyclonal antibodies specific for VH 1-VH 6 gene families and monoclonal antibodies (MAb) recognising CRI linked to theVH 1, VH 3, VH 4 and VH 6 gene families. The results revealed that the VH 3 family (60. 5%) was the most predominant gene family...
2000: Pathology Oncology Research: POR
https://read.qxmd.com/read/1203882/mutiple-myeloma-resistant-to-melphalan-nsc-8806-treated-with-cyclophosphamide-nsc-26271-prednisone-nsc-10023-and-chloroquine-nsc-187208
#16
RANDOMIZED CONTROLLED TRIAL
R A Kyle, B R Seligman, H J Wallace, R T Silver, O Glidewell, J F Holland
A prospective randomized study of the effects of two different therapeutic regimens was conducted in 41 patients with multiple myeloma resistant to therapy with melphalan. The results of treatment with cyclophosphamide plus prednisone were compared with those of cyclophosphamide, prednisone, and chloroquine. Chloroquine, which inhibits the repair process of DNA in animals, has reportedly produced responses to alkylating agents to which the animal had been resistant. No significant differences in response to the doses used with either regimen could be found...
May 1975: Cancer Chemotherapy Reports. Part 1
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.